Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1
about
PASS-based approach to predict HIV-1 reverse transcriptase resistance.Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.Determination of Phenotypic Resistance Cutoffs From Routine Clinical DataCombinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infantsPhenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men.Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.Genotypic predictors of human immunodeficiency virus type 1 drug resistance.Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.Therapeutic amprenavir concentrations in cerebrospinal fluidDrug resistance and antiretroviral drug development.Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assaysPanel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations.Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs.Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitorsHuman immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals.Use of tissue culture cell lines to evaluate HIV antiviral resistance.A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration.
P2860
Q30490600-DB31ADEB-8A86-4CE6-A410-7F69717EF64FQ30564087-A772B048-8588-42A2-B9BA-AC4148C0D007Q31139379-319DDAAD-FD37-421A-B7C2-4BA6B382A001Q33535654-9A93D5CA-41E3-4218-9450-2341BB1DE5CBQ33561750-B47A7E70-F638-4A6A-9605-1D9C0B6FDD5BQ33780566-04CF786D-0A4F-4881-B454-6F6B555D7EF9Q33887266-0FE002BE-30D2-4392-B330-F9902A6FC8BFQ33935458-AF2B18DF-26D6-45EE-9BFA-23E6264D2FC7Q33962846-E45CF1CE-BA7B-491C-A533-6BD8AB9FFBEFQ34123595-F049FEDC-4946-4165-ABC3-3BFD09D04364Q34129231-3A7F55C9-1431-4656-9103-31C940625FA8Q34429204-701E59E9-E4FC-4F4D-8F14-4AFA3FECC656Q34481352-CCEED64B-6D2B-4190-A6B7-2A6F788BA202Q34489239-FD9DB95C-AFDD-4E2B-8119-EC948560A9CEQ34635561-B9B12931-6866-4658-A783-D61B7D4F9288Q35051539-87254797-32E5-4F15-85D6-C67E035670A8Q35105844-408D06C9-369A-4463-B417-26E3223BA63EQ35108499-385693DF-6F60-4B0F-87E5-3B0B4C44F196Q35300021-8A9FA3CE-5A4F-4694-956A-353D8692E21EQ35404442-BFF4975A-1172-4909-96EE-99269755C8B3Q35784750-82BCAA22-A526-4DD3-B3AD-04C57A348A7AQ35867483-9147F30C-0F76-48F4-B338-0CA508827C3EQ36104277-4C0C0B7D-978B-4760-82CE-B0AFBCD401BCQ36347325-E3C8CB29-56B0-4821-98BF-CD14754F3782Q36430073-77962486-7C13-4EC8-8DC7-75A0BEBE8A1DQ36573340-53EB9DA8-35E9-4561-8C13-14E498DF8AEBQ36667153-B4EFF054-D736-4549-8DC5-06D9F4B2DDDBQ36673315-60755601-AFE6-4AEB-8FC4-4D143F0E31B7Q36899994-3CCE733B-A956-4ECD-AEA8-412168EE0124Q36950131-6AEE00AA-1916-49FC-A081-DB61500E1A2BQ37204271-27C00A77-1A1F-4757-9355-0279F86F4580Q37256312-71B50F7D-6058-4101-8B32-0164B74D5525Q37263541-5BE09E88-3264-48B0-8450-D4222E6DE94EQ37410823-D66F3D1F-AFDE-472B-A4FE-453D95672844Q37624829-E0E7238F-C937-4B55-8BDC-DAF10B240F58Q38759542-8BFC7000-0830-46BB-9F6A-53D22E9CF842Q39955277-1B43D470-C276-4C4E-B72D-32BDB32506A4Q40042881-90F8D621-06B5-4B03-BAD9-02F2C0C10C7DQ40104085-3D49522E-2A00-49F1-AC7D-205E496AAABBQ40181126-A99527D6-3827-43B4-B8E4-226737649678
P2860
Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1
@en
type
label
Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1
@en
prefLabel
Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1
@en
P2093
P2860
P1476
Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1
@en
P2093
C J Petropoulos
J M Whitcomb
N S Hellmann
N T Parkin
P2860
P304
P356
10.1128/AAC.48.2.437-443.2004
P407
P577
2004-02-01T00:00:00Z